IN VITRO SYNERGISM BETWEEN MICONAZOLE AND GRISEOFULVIN AGAINST CANDIDA SPECIES

Objective: To find the synergistic effect between miconazole and griseofulvin on common human Candida. Methods: A serial dilution of miconazole and griseofulvin in Yeast Nitrogen Base (YNB) was prepared in test tubes. 50i l of standardised suspension of yeasts was inoculated into each test tube and incubated at 30 o C for 24-48 hours. The antifungal activity of miconazole alone or with griseofulvin was measured in vitro against 300 isolates of the Candida. Results: Miconazole and griseofulvin in combination showed a Minimum Inhibitory Concentration (MIC) of 6.7mg/l miconazole (M) and 20mg/l griseofulvin (G) for C. albicans, 13mg/l M and 20mg/l G for C. tropicalis, 4.9mg/l M and 20mg/l G for C. pseudotropicalis and 14.2mg/l M and 20mg/l G for C. parapsilosis. The combination of miconazole with griseofulvin resulted in synergistic activity (Fractional Inhibitory Concentration, FIC <0.82) against C. albicans in a microdilution checkerboard assay. FICs for other species were as follow: FIC <0.75 for C. tropicalis, FIC <0.86 for C. pseudotropicalis and FIC <0.79 for C. parapsilosis. Conclusion: These results suggest that combination of griseofulvin and miconazole regimens may reduce usual dosage of miconazole and it is helpful in the control of infections caused by Candida species.

[1]  V. Lorian.  Antibiotics in laboratory medicine , 2005 .

[2]  A. Elkarmi,et al.  Isolation and characterization of Candida spp. in Jordanian cancer patients: prevalence, pathogenic determinants, and antifungal sensitivity. , 2004, Japanese journal of infectious diseases.

[3]  H. Yamaguchi,et al.  Comparative Evaluation of Standard Dilution Method and Commercial Kit for Frozen Plate Antifungal Susceptibility Testing of Yeasts Using 200 Clinical Isolates , 2004, Microbiology and immunology.

[4]  T. Walsh,et al.  Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. , 2003, The Journal of infectious diseases.

[5]  J. Sobel,et al.  A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  M. Bergervoet,et al.  In Vitro Interaction of Flucytosine Combined with Amphotericin B or Fluconazole against Thirty-Five Yeast Isolates Determined by both the Fractional Inhibitory Concentration Index and the Response Surface Approach , 2002, Antimicrobial Agents and Chemotherapy.

[7]  T J Walsh,et al.  New drugs and novel targets for treatment of invasive fungal infections in patients with cancer. , 2000, The oncologist.

[8]  N. Georgopapadakou,et al.  Antifungals: mechanism of action and resistance, established and novel drugs. , 1998, Current opinion in microbiology.

[9]  J. Tillement,et al.  Systemic Antifungal Agents , 1998, Drug safety.

[10]  E. Johnson,et al.  In-vitro resistance to imidazole antifungals in Candida albicans. , 1984, The Journal of antimicrobial chemotherapy.

[11]  G. Eliopoulos,et al.  Antibiotic synergism and antimicrobial combinations in clinical infections. , 1982, Reviews of infectious diseases.

[12]  A. Oehlschlager,et al.  Lipid composition and polyene antibiotic resistance of Candida albicans mutants. , 1978, Canadian journal of biochemistry.